Treatment

RELUGOLIX clinical trials

1 indexed studies · 0 currently recruiting

AuthorisedTherapeutic exploratory (Phase II)
Ultra-hypofractionated radiotHErapy and concomitant oral RelugOlix for treatment of intermediate risk prostate cancer. (Ultra-HERO)
This study looks at a new way to treat prostate cancer. It combines a special, shorter course of radiation therapy with a new oral medicine called relugolix. The aim is to see how well this treatment can lower a specific marker (PSA) in the blood for men with intermediate-risk prostate cancer.
For: Intermediate risk prostate cancer
Italy